A Phase I Study of TJ033721 Immunotherapy in People with Advanced Pancreatic or Esophagogastric Cancer


Full Title

A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors


The purpose of this study is to find the highest dose of the investigational immunotherapy drug TJ033721 that can be given safely in people with advanced cancers of the pancreas, esophagus, stomach, or junction between the esophagus and stomach. TJ033721 is an antibody that binds to Claudin 18.2, a protein expressed on some cancers cells, and to 4-1BB, a protein found on immune cells. TJ033721 may strengthen the immune system’s ability to fight cancer cells by activating a patient’s own cells to destroy the tumor. It is given intravenously (by vein).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced cancer of the pancreas, esophagus, stomach, or junction between the esophagus and stomach that cannot be successfully treated using standard therapies.
  • At least 4 weeks must pass between the completion of prior therapies and receipt of TJ033721.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for people age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Geoffrey Ku at 646-888-4588.




Phase I (phase 1)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID